gdc-0810
Small moleculeexperimental
Clinical trial activity
5 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Dec 29, 2014 (NCT01823835)
Timeline
Indications
Mechanism of action
- Estrogen receptorINHIBITOR
Estrogen receptor inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545390 ↗
Also known as
- 3-(4-(2-(2-chloro-4-fluorophenyl)-1-(1h-indazol-5-yl)but-1-en-1-yl)phenyl)acrylic acid
- arn-810
- arn-810
- arn-810
- gdc-0810
- gdc-0810
- gdc-0810
- gdc-0810
- gdc-0810
- rg-6046
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02802670 | Phase 1 | May 1, 2016 | Genentech, Roche |
| NCT02722018 | Phase 1 | Dec 29, 2015 | Genentech, Roche |
| NCT02569801 | Phase 2 | Dec 5, 2015 | Genentech, Roche |
| NCT02621957 | Phase 1 | Dec 1, 2015 | Genentech, Roche |
| NCT01823835 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2014 | Genentech, Roche |
Showing 5 of 5 trials
Page 1 / 1